TW200423922A - Method of treatment with nelfinavir - Google Patents

Method of treatment with nelfinavir Download PDF

Info

Publication number: TW200423922A
Authority: TW; Taiwan
Prior art keywords: fat; food; administration; auc; veraset
Prior art date: 2003-02-10

Application number

TW093102921A

Other languages

English (en)

Chinese (zh)

Inventor

Carolyn Petersen

Edward Fu Ceayong Pun

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-10

Filing date

2004-02-09

Publication date

2004-11-16

2004-02-09 Application filed by Pfizer filed Critical Pfizer

2004-11-16 Publication of TW200423922A publication Critical patent/TW200423922A/zh

Links

238000011282 treatment Methods 0.000 title claims description 16
238000000034 method Methods 0.000 title abstract description 31
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 title abstract description 9
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 title abstract description 6
229960000884 nelfinavir Drugs 0.000 title abstract description 6
235000013305 food Nutrition 0.000 claims abstract description 50
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 22
241000124008 Mammalia Species 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
238000012360 testing method Methods 0.000 claims description 34
235000003642 hunger Nutrition 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 20
230000037351 starvation Effects 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 9
239000012453 solvate Substances 0.000 claims description 5
230000003287 optical effect Effects 0.000 claims description 4
229940002612 prodrug Drugs 0.000 claims description 3
239000000651 prodrug Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims 1
241000517096 Zele Species 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
239000003925 fat Substances 0.000 description 112
235000019197 fats Nutrition 0.000 description 104
235000012054 meals Nutrition 0.000 description 101
210000002381 plasma Anatomy 0.000 description 30
235000004213 low-fat Nutrition 0.000 description 25
230000000694 effects Effects 0.000 description 23
230000036470 plasma concentration Effects 0.000 description 19
235000021152 breakfast Nutrition 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000003826 tablet Substances 0.000 description 10
238000011260 co-administration Methods 0.000 description 8
238000011156 evaluation Methods 0.000 description 8
238000012545 processing Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
239000007937 lozenge Substances 0.000 description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000009246 food effect Effects 0.000 description 6
235000013336 milk Nutrition 0.000 description 6
239000008267 milk Substances 0.000 description 6
210000004080 milk Anatomy 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
235000012631 food intake Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 5
239000006071 cream Substances 0.000 description 4
WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
108010010369 HIV Protease Proteins 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
244000269722 Thea sinensis Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
235000013351 cheese Nutrition 0.000 description 3
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000021471 food effect Nutrition 0.000 description 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
235000021193 standardized breakfast Nutrition 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
240000000560 Citrus x paradisi Species 0.000 description 2
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000124033 Salix Species 0.000 description 2
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
229960001830 amprenavir Drugs 0.000 description 2
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 2
239000012491 analyte Substances 0.000 description 2
235000008429 bread Nutrition 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
229960002656 didanosine Drugs 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
229960003804 efavirenz Drugs 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
239000004030 hiv protease inhibitor Substances 0.000 description 2
229960001936 indinavir Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
-1 polypropylene Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
229940023080 viracept Drugs 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010048474 Fat redistribution Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
229940122440 HIV protease inhibitor Drugs 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
241000519695 Ilex integra Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
229960004748 abacavir Drugs 0.000 description 1
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
229960001997 adefovir Drugs 0.000 description 1
229960003205 adefovir dipivoxil Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229960003362 carbutamide Drugs 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229940014461 combivir Drugs 0.000 description 1
239000002131 composite material Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229940088900 crixivan Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
229960005319 delavirdine Drugs 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940072253 epivir Drugs 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
235000013410 fast food Nutrition 0.000 description 1
230000035558 fertility Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
235000021153 full breakfast Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229940125777 fusion inhibitor Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
XGFJCRNRWOXGQM-UHFFFAOYSA-N hot-2 Chemical compound CCSC1=CC(OC)=C(CCNO)C=C1OC XGFJCRNRWOXGQM-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229960004525 lopinavir Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
229950002475 mesilate Drugs 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
HPXIKMBHOXLFOR-LICLKQGHSA-N n-[(e)-(3,4-dimethoxyphenyl)methylideneamino]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1\C=N\NC(=O)C1=CC=NC=C1 HPXIKMBHOXLFOR-LICLKQGHSA-N 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
229940063627 rescriptor Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960000311 ritonavir Drugs 0.000 description 1
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
229960001852 saquinavir Drugs 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
238000000926 separation method Methods 0.000 description 1
FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 description 1
238000004088 simulation Methods 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960001203 stavudine Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229940054565 sustiva Drugs 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229950004348 verazide Drugs 0.000 description 1
229940098802 viramune Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
229940052255 ziagen Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW093102921A 2003-02-10 2004-02-09 Method of treatment with nelfinavir TW200423922A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44644403P	2003-02-10	2003-02-10
US52425803P	2003-11-21	2003-11-21

Publications (1)

Publication Number	Publication Date
TW200423922A true TW200423922A (en)	2004-11-16

Family

ID=32853430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW093102921A TW200423922A (en)	2003-02-10	2004-02-09	Method of treatment with nelfinavir

Country Status (13)

Country	Link
EP (1)	EP1605942A1 (pt)
JP (1)	JP2006517221A (pt)
AR (1)	AR043133A1 (pt)
BR (1)	BRPI0407174A (pt)
CA (1)	CA2515095A1 (pt)
CL (1)	CL2004000202A1 (pt)
MX (1)	MXPA05008425A (pt)
NL (1)	NL1025449C2 (pt)
PA (1)	PA8595301A1 (pt)
PE (1)	PE20040948A1 (pt)
TW (1)	TW200423922A (pt)
UY (1)	UY28183A1 (pt)
WO (1)	WO2004069251A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7157455B2 (en)	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives

2004
- 2004-01-29 WO PCT/IB2004/000313 patent/WO2004069251A1/en not_active Ceased
- 2004-01-29 EP EP04706250A patent/EP1605942A1/en not_active Withdrawn
- 2004-01-29 BR BR0407174-3A patent/BRPI0407174A/pt not_active IP Right Cessation
- 2004-01-29 CA CA002515095A patent/CA2515095A1/en not_active Abandoned
- 2004-01-29 MX MXPA05008425A patent/MXPA05008425A/es unknown
- 2004-01-29 JP JP2006502411A patent/JP2006517221A/ja active Pending
- 2004-02-05 CL CL200400202A patent/CL2004000202A1/es unknown
- 2004-02-09 PA PA20048595301A patent/PA8595301A1/es unknown
- 2004-02-09 PE PE2004000146A patent/PE20040948A1/es not_active Application Discontinuation
- 2004-02-09 AR ARP040100399A patent/AR043133A1/es unknown
- 2004-02-09 TW TW093102921A patent/TW200423922A/zh unknown
- 2004-02-10 UY UY28183A patent/UY28183A1/es not_active Application Discontinuation
- 2004-02-10 NL NL1025449A patent/NL1025449C2/nl not_active IP Right Cessation

Also Published As

Publication number	Publication date
PE20040948A1 (es)	2004-12-27
BRPI0407174A (pt)	2006-02-07
NL1025449A1 (nl)	2004-08-12
CA2515095A1 (en)	2004-08-19
JP2006517221A (ja)	2006-07-20
MXPA05008425A (es)	2005-10-19
EP1605942A1 (en)	2005-12-21
NL1025449C2 (nl)	2005-03-15
WO2004069251A1 (en)	2004-08-19
PA8595301A1 (es)	2005-08-04
AR043133A1 (es)	2005-07-20
UY28183A1 (es)	2004-09-30
CL2004000202A1 (es)	2005-03-18

Publication	Publication Date	Title
Fujioka et al.	2006	The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome
Shabert et al.	1999	Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial
Hendeles et al.	1985	Food-induced “dose-dumping” from a once-a-day theophylline product as a cause of theophylline toxicity
Falcoz et al.	2002	Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers
Finestone et al.	2001	Quantifying fluid intake in dysphagic stroke patients: a preliminary comparison of oral and nonoral strategies
Gill et al.	2022	A randomized dietary intervention to increase colonic and peripheral blood SCFAs modulates the blood B-and T-cell compartments in healthy humans
RU2640561C2 (ru)	2018-01-09	Повышение биодоступности лекарственных средств при терапии налтрексоном
ES2404694T3 (es)	2013-05-28	Composición de manano oligosacárido para la reducción de grasa corporal
WO2015200842A1 (en)	2015-12-30	Composition comprising metformin and a microbiome modulator
AU2014332200B2 (en)	2018-10-04	HIV treatment formulation of atazanavir and cobicistat
US20240358664A1 (en)	2024-10-31	Vigabatrin liquid pharmaceutical composition
WO2012074375A1 (en)	2012-06-07	Prevention or treatment of overweight and obesity in type 2 diabetic patients
WO2008141368A1 (en)	2008-11-27	Combination laxative compositions comprising a colonic stimulant and a bulking laxative
van der Lee et al.	2006	Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children
McLachlan et al.	2006	Meals and medicines
Teo et al.	2000	Effect of a high‐fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women
Boyd et al.	2003	Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
Masuzaki et al.	2020	Safety and efficacy of nanoparticulated brown rice germ extract on reduction of body fat mass and improvement of fuel metabolism in both pre-obese and mild obese subjects without excess of visceral fat accumulation.
TW200423922A (en)	2004-11-16	Method of treatment with nelfinavir
Gavin et al.	2002	The role of protease inhibitor therapy in children with HIV infection
KR20190019061A (ko)	2019-02-26	지연된 방출 경구 탐술로신 하이드로클로라이드
AU2016398923A1 (en)	2018-11-15	Formulation and method for the prevention and/or treatment of hangover symptoms
Ueda et al.	2015	Chrysanthemum flower oil inhibits diet-induced serum uric acid elevation in adult male subjects: A randomised, double-blind, placebo-controlled cross-over comparison study
Prescott et al.	1993	Impaired absorption of paracetamol in vegetarians.
US20040186066A1 (en)	2004-09-23	Method of treatment with nelfinavir